Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760906 | 0.97 | KDM4E (0.52) | KDM4EMAPTHPGDMEN1KMT2A | |
| SCHEMBL5789643 | 0.87 | FPR2 (0.44) | KDM4EMAPTHPGDMEN1KMT2A | |
| SCHEMBL5763072 | 0.86 | ROCK2 (0.55) | KDM4EMAPTDRD2DRD3ROCK2 | |
| SCHEMBL5762942 | 0.85 | ROCK2 (0.49) | KDM4EMAPTDRD2DRD3ROCK2 | |
| SCHEMBL5763103 | 0.84 | HPGD (0.43) | KDM4EMAPTHPGDMEN1KMT2A | |
| SCHEMBL5762686 | 0.83 | FPR2 (0.48) | KDM4EMAPTSMN1; SMN2DRD2DRD3 | |
| SCHEMBL5759864 | 0.82 | FPR2 (0.50) | KDM4EMAPTSMN1; SMN2DRD2DRD3 | |
| SCHEMBL5845894 | 0.82 | KDM4E (0.41) | KDM4EMAPTHPGDMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5808241 | 0.82 | FPR2 (0.47) | KDM4EMAPTSMN1; SMN2DRD2DRD3 | |
| SCHEMBL5761228 | 0.82 | DRD2 (0.40) | KDM4EMAPTDRD2DRD3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101885-B2 | 1-(4-Bromo-phenyl)-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one; antagonists of the serotonin 5HT1B receptor; treating depression | PFIZER INC (US) | 2006-09-05 | — | — | US | claimed |
| EP-1638932-A1 | NOVEL PIPERAZINYL-ARYLOXY AND PIPERAZINYL-HETEROARYLOXY-N-ARYL LACTAMS | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | claimed |
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | PFIZER INC | 2004-12-30 | — | — | US | claimed |
| WO-2004110994-A1 | NOVEL PIPERAZINYL-ARYLOXY AND PIPERAZINYL-HETEROARYLOXY-N-ARYL LACTAMS | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | claimed |
| US-7101885-B2 | 1-(4-Bromo-phenyl)-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one; antagonists of the serotonin 5HT1B receptor; treating depression | PFIZER INC (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | OPRD1, HTR5A, PTGDR | KDM4E 2741/4885MAPT 2883/4885HPGD 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.